Division Head and Tenured Professor, Division of Cancer Immune Regulation
Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University
The Center for Cancer Immunotherapy and Immunobiology (CCII) was established in April 2020 as an affiliated education and research facility of the Kyoto University Graduate School of Medicine to take the global lead in resolving various issues in cancer immunology and immunotherapy as well as contribute to rapid improvements in cancer care through the use of cutting-edge knowledge and technologies.
The first director of the CCII is Tasuku Honjo, distinguished professor of Kyoto University Institute for Advanced Study (KUIAS) and co-recipient of the 2018 Nobel Prize in Physiology or Medicine for the discovery of PD-1. The CCII plans to establish six divisions—three for basic research and three for clinical research.
The CCII invites applications for a Division Head and Tenured Professor of the Division of Cancer Immune Regulation. While the Division of Cancer Immune Regulation takes a perspective on clinical cancer research, it aims to elucidate the mechanism of cancer immune regulation based on basic research. We welcome applications from researchers in the field of cancer immunology who will lead the worldwide cancer immunology research.
The successful candidate will receive competitive start-up funds for the first five years after arrival.
Additional information about this position, including how to apply for the position, is available via the CCII’s website (https://www.ccii.med.kyoto-u.ac.jp/en/).